Targacept

CompanyUnited States

Targacept develops one asset, in phase 2, no development reported (ispronicline in Alzheimer's disease). Mostly small molecule acting on CHRNA4 and CHRNB2; based in the United States.

1
Asset
Furthest stage
Phase 2, no development reported
2
Trials
0
Signals

Pipeline

1
  • ispronicline

    Neuronal nicotinic acetylcholine receptor (alpha4beta2) agonist designed to enhance cognitive function.

    Phase 2, no development reported, Small molecule, CHRNA4, CHRNB2, Alzheimer's disease, attention deficit hyperactivity disorder

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials3
  • Similar companies6

Intelligence